https://scholars.lib.ntu.edu.tw/handle/123456789/495061
標題: | Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR | 作者: | KUEI-PIN CHUNG SHANG-GIN WU Wu J.-Y. CHIH-HSIN YANG CHONG-JEN YU Wei P.-F. JIN-YUAN SHIH PAN-CHYR YANG |
公開日期: | 2012 | 卷: | 18 | 期: | 12 | 起(迄)頁: | 3470-3477 | 來源出版物: | Clinical Cancer Research | 摘要: | Purpose: Several deletions in exon 19 of epidermal growth factor receptor (EGFR) gene have been reported in non-small cell lung cancer (NSCLC). It is unknown if deletions occurring at different amino acid positions or of different sizes are associated with different clinical outcome to EGFR tyrosine kinase inhibitors (TKI). Experimental Design: This study enrolled NSCLC patients with deletions in EGFR exon 19. Patients who had received EGFR TKIs for advanced NSCLC were further evaluated for response rate (RR), progression-free survival (PFS), and overall survival (OS). Results: In 308 patients with deletions in EGFR exon 19, 298 had deletions encompassing the entire amino acid string from L747 through E749 (LRE deletions). EGFR TKIs were used in 204 patients with advanced NSCLC. Patients with non-LRE deletions had the least RR, compared with those with deletions from E746 or L747 (42.9%, 68.2%, and 79.6%, respectively; P = 0.022). Patients with non-LRE deletions had relatively short median PFS, though not significantly different from those with deletions from E746 or L747 (5.9, 9.8, and 10.5 months, respectively; P = 0.665). The OS was not different among patients with deletions occurring at different amino acid positions (P = 0.776). Deletions in exon 19 of different sizes were not associated with different RR, PFS, or OS. Conclusions: Non-LRE deletions in exon 19 were associated with worse response to EGFR TKIs, compared with LRE deletions. Therefore, the expected clinical outcome under EGFR TKIs depends on not only the existence but also the types of deletions in exon 19. ?2012 AACR. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862542771&doi=10.1158%2f1078-0432.CCR-11-2353&partnerID=40&md5=adee5e71e32214874afdc8ef13a9aa43 https://scholars.lib.ntu.edu.tw/handle/123456789/495061 |
ISSN: | 1078-0432 | DOI: | 10.1158/1078-0432.CCR-11-2353 | SDG/關鍵字: | epidermal growth factor receptor; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; adult; advanced cancer; aged; amino acid sequence; article; controlled study; drug response; EGFR gene; exon; female; gene; gene deletion; human; human tissue; lung non small cell cancer; major clinical study; male; overall survival; priority journal; progression free survival; retrospective study; treatment outcome; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Receptor, Epidermal Growth Factor; Sequence Analysis, Protein; Sequence Deletion; Treatment Outcome |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。